摘要
目的探讨雌、孕激素受体在女性乳腺癌与各种增生性病变组织中的表达及临床意义。方法取2006年2月至2007年2月中日联谊医院乳腺甲状腺外科手术后经病理科诊断证实的病例,乳腺增生性疾病52例(40人),乳腺癌52例(49人)。其中普通型增生10例,轻度非典型增生12例,中度非典型增生9例,重度非典型增生21例,乳腺浸润性导管癌52例。用免疫组化SP法检测ER、PR的表达。结果在乳腺普通型增生、轻、中、重度非典型增生及乳腺浸润性导管癌组织中ER表达的阳性率分别为30.00%、41.67%、44.44%、61.90%和69.23%,PR表达的阳性率分别为20.00%、25.00%、44.44%、52.38%和55.77%,ER阳性和/或PR阳性率分别为30.00%、41.67%、55.56%、66.67%、69.23%,仅普通型增生与乳腺癌组织中有显著性差异。结论(1)乳腺普通型增生与乳腺癌组织无明显联系。其余三种非典型增生组织中ER、PR阳性表达率与乳腺癌组织差异不显著,且其相关性由轻、中、重度逐级递增。(2)ER、PR表达强度的逐级递增及单细胞中强阳性(+++)率的逐级增高表明这一过程与雌激素过刺激有关,因此对乳腺增生性疾病行ER、PR检测有利于早期发现乳腺癌,根据ER、PR检测结果判断病变向乳腺癌发展的风险性。(3)在ER和/或PR阳性的乳腺增生性疾病患者中可以考虑应用内分泌治疗。
Objective To observe the expression and clinical implication of estrogen receptors and progestogen receptors in hyperplastic lesions and malignant lesions of breast.Methods Here is a retrospective research.The relevant features of 40 patients(52 breasts) who had hyperplastic disease resected in the Breast and Thyroid Surgery Department of China-Japan Union Hospital of Jilin University.In control group,tissue was obtained from a series of 50 patients(52 breasts) who had malignant breast neoplasm resected.By SP of immunohistochemical method.Results The expressions of ER in pure hyperplastic lesions,light,moderate,severe hyperplastic lesions and malignant lesions are 30.00%,41.67%,44.44%,61.90%and 69.23%.The expressions of PR are 20.00%,25.00%,44.44%,52.38%和55.77%.The expressions of ER positive and/or PR positive are 30.00%、41.67%、55.56%、66.67%and 69.23%.Conclusion (1)The expressions of ER,PR between pure hyperplastic lesions and breast neoplasm is remarkable.The pertinency between light,moderate,severe hyperplastic lesions and breast neoplasm is gradually increased.(2)We can judge the potential risk of a hyperplastic lesion by its expression of ER,PR.(3)The retrospective research can provide a gist to do the endocrine therapy on some hyperplastic mammary diseases.
出处
《中国实验诊断学》
2007年第11期1478-1481,共4页
Chinese Journal of Laboratory Diagnosis
关键词
乳腺癌
增生性病变
非典型增生
雌激素受体
孕激素受体
breast neoplasm
hyperplastic lesions
atypical hyperplastic disease
estrogen receptors
progestogen receptors
